UA94062C2 - Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of leukemia - Google Patents

Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of leukemia

Info

Publication number: UA94062C2
Authority: UA; Ukraine
Prior art keywords: methods; treatment; leukemia; isoindol; dione
Prior art date: 2005-10-04

Application number

UAA200805327A

Other languages

English (en)

Inventor

Джером Б. Зелдис

Original Assignee

Селджин Корпорэйшн

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-04

Filing date

2006-03-10

Publication date

2011-04-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37603038&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA94062(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-03-10 Application filed by Селджин Корпорэйшн filed Critical Селджин Корпорэйшн

2011-04-11 Publication of UA94062C2 publication Critical patent/UA94062C2/ru

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Plural Heterocyclic Compounds (AREA)

UAA200805327A 2005-10-04 2006-03-10 Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of leukemia UA94062C2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US11/244,117 US7393862B2 (en)	2002-05-17	2005-10-04	Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias

Publications (1)

Publication Number	Publication Date
UA94062C2 true UA94062C2 (en)	2011-04-11

Family

ID=37603038

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200805327A UA94062C2 (en)	2005-10-04	2006-03-10	Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of leukemia

Country Status (18)

Country	Link
US (7)	US7393862B2 (ru)
EP (2)	EP1931343A2 (ru)
JP (4)	JP5916977B2 (ru)
KR (3)	KR20080058469A (ru)
CN (2)	CN103142594A (ru)
AR (1)	AR057868A1 (ru)
AU (1)	AU2006299431B2 (ru)
BR (1)	BRPI0616670A2 (ru)
CA (2)	CA2570755A1 (ru)
IL (1)	IL190437A (ru)
NO (1)	NO20082068L (ru)
NZ (1)	NZ567049A (ru)
PE (1)	PE20070761A1 (ru)
RU (2)	RU2406501C2 (ru)
TW (1)	TWI415610B (ru)
UA (1)	UA94062C2 (ru)
WO (1)	WO2007041637A2 (ru)
ZA (1)	ZA200803700B (ru)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7968569B2 (en)	2002-05-17	2011-06-28	Celgene Corporation	Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7393862B2 (en) *	2002-05-17	2008-07-01	Celgene Corporation	Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
USRE48890E1 (en)	2002-05-17	2022-01-11	Celgene Corporation	Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US8404716B2 (en)	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en)	2002-10-15	2021-09-14	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US20050100529A1 (en) *	2003-11-06	2005-05-12	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
WO2007027527A2 (en)	2005-08-31	2007-03-08	Celgene Corporation	Isoindole-imide compounds and compositions comprising and methods of using the same
US20080095768A1 (en) *	2006-08-07	2008-04-24	Pdl Biopharma, Inc.	Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
US8877780B2 (en)	2006-08-30	2014-11-04	Celgene Corporation	5-substituted isoindoline compounds
HUE035389T2 (en)	2006-09-26	2018-05-02	Celgene Corp	5-substituted quinazolinone derivatives as anticancer agents
US20090175869A1 (en) *	2007-05-31	2009-07-09	Ascenta Therapeutics, Inc.	Pulsatile Dosing of Gossypol for Treatment of Disease
NZ584425A (en)	2007-09-26	2012-03-30	Celgene Corp	6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
WO2009058394A1 (en) *	2007-11-01	2009-05-07	Celgene Corporation	Cytidine analogs for treatment of myelodysplastic syndromes
US20100310563A1 (en) *	2007-11-30	2010-12-09	Bumm Thomas G P	Methods for treating induced cellular proliferative disorders
EP2235535B1 (en) *	2007-12-07	2014-11-12	Celgene Corporation	Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma
MX2010009344A (es) *	2008-03-11	2012-09-28	Reddys Lab Ltd Dr	Preparacion de lenalidomida.
US20090298882A1 (en) *	2008-05-13	2009-12-03	Muller George W	Thioxoisoindoline compounds and compositions comprising and methods of using the same
SI2358697T1 (sl)	2008-10-29	2016-02-29	Celgene Corporation	Spojine izoindolina za uporabo pri zdravljenju raka
EP2355802A1 (de) *	2008-11-14	2011-08-17	Ratiopharm GmbH	Intermediate und orale darreichungsformen enthaltend lenalidomid
WO2010093434A1 (en)	2009-02-11	2010-08-19	Celgene Corporation	Isotopologues of lenalidomide
HUE043862T2 (hu)	2009-05-19	2021-12-28	Celgene Corp	4-Amino-2-(2,6-dioxopiperidin-3-il)-izoindolin-l,3-diont tartalmazó készítmények
EP2436387B1 (en)	2009-05-25	2018-07-25	Celgene Corporation	Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
CA2780998C (en) *	2009-11-24	2016-07-12	Celgene Corporation	Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells
BR112012015129A2 (pt)	2009-12-22	2019-09-24	Celgene Corp	"composto, composição farmacêutica e método para tratar, controlar ou prevenir uma doença ou distúrbio"
WO2011084968A1 (en)	2010-01-05	2011-07-14	Celgene Corporation	A combination of an immunomodulatory compound and an artemisinin or a derivative thereof for treating cancer
SG10202012179RA (en)	2010-02-11	2021-01-28	Celgene Corp	Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
CN103068386A (zh) *	2010-03-12	2013-04-24	细胞基因公司	使用来那度胺治疗非霍奇金淋巴瘤的方法及作为预测因子的基因和蛋白质生物标记
ES3034958T3 (en) *	2010-08-27	2025-08-27	Univ Southern California	Pharmaceutical compositions comprising derivatives of perillyl alcohol
US20160038600A1 (en)	2012-08-03	2016-02-11	Neonc Technologies Inc.	Pharmaceutical compositions comprising poh derivatives
US9913838B2 (en)	2010-08-27	2018-03-13	Neonc Technologies, Inc.	Methods of treating cancer using compositions comprising perillyl alcohol derivative
WO2012079075A1 (en)	2010-12-10	2012-06-14	Concert Pharmaceuticals, Inc.	Deuterated phthalimide derivatives
US8853175B2 (en)	2011-01-10	2014-10-07	Celgene Corporation	Phenethylsulfone isoindoline derivatives and their use
PL2683708T3 (pl)	2011-03-11	2018-03-30	Celgene Corporation	Postacie stałe 3-(5-amino-2-metylo-4-okso-4h-chinazolin-3-ylo)-piperydyno-2,6-dionu oraz ich kompozycje farmaceutyczne i zastosowania
SI2683384T1 (sl)	2011-03-11	2016-05-31	Celgene Corporation	Metode zdravljenja raka z uporabo 3-(5-amino-2-metil-4-okso-4H-kinazolin-3-il)-piperidin-2,6-diona
WO2012135299A1 (en)	2011-03-28	2012-10-04	Deuteria Pharmaceuticals Inc	2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
JP6016892B2 (ja)	2011-04-29	2016-10-26	セルジーンコーポレイション	セレブロンを予測因子として使用する癌及び炎症性疾患の治療方法
WO2012177678A2 (en)	2011-06-22	2012-12-27	Celgene Corporation	Isotopologues of pomalidomide
CN105142615A (zh)	2011-09-14	2015-12-09	细胞基因公司	环丙烷羧酸{2-[(1s)-1-(3-乙氧基-4-甲氧基-苯基)-2-甲烷磺酰基-乙基]-3-氧代-2,3-二氢-1h-异吲哚-4-基}-酰胺的制剂细胞基因公司公司设立的州：特拉华州
CN103890667B (zh)	2011-10-21	2017-02-15	谷歌公司	用户友好、网络连接的学习型恒温器及相关系统和方法
SMT202000339T1 (it)	2011-12-27	2020-07-08	Amgen Europe Gmbh	FORMULAZIONI DI (+)-2-[1-(3-ETOSSl-4-METOSSI-FENIL)-2-METANSOLFONIL-ETIL]-4-ACETILAMMINOISOINDOLIN-1,3-DIONE
WO2013130849A1 (en)	2012-02-29	2013-09-06	Concert Pharmaceuticals, Inc.	Substituted dioxopiperidinyl phthalimide derivatives
US9249093B2 (en)	2012-04-20	2016-02-02	Concert Pharmaceuticals, Inc.	Deuterated rigosertib
ES3013301T3 (en)	2012-06-29	2025-04-11	Celgene Corp	Methods for determining drug efficacy using ikzf3 (aiolos)
EP2870973B1 (en) *	2012-07-06	2022-08-31	St. Marianna University School of Medicine	Remedy for htlv-1-associated myelopathy patients
CN104508058A (zh) *	2012-08-09	2015-04-08	罗门哈斯公司	包含杀生物剂的涂料组合物
HRP20190398T1 (hr)	2012-08-09	2019-05-17	Celgene Corporation	Čvrsti oblik (s)-3-(4-((4-morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-dion hidroklorida
SG10202108516PA (en)	2012-08-09	2021-09-29	Celgene Corp	Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
US9587281B2 (en)	2012-08-14	2017-03-07	Celgene Corporation	Cereblon isoforms and their use as biomarkers for therapeutic treatment
US9643950B2 (en)	2012-10-22	2017-05-09	Concert Pharmaceuticals, Inc.	Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}
WO2014110322A2 (en)	2013-01-11	2014-07-17	Concert Pharmaceuticals, Inc.	Substituted dioxopiperidinyl phthalimide derivatives
JP6359563B2 (ja)	2013-01-14	2018-07-18	デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ，ＬＬＣ	３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体
EP2764866A1 (en)	2013-02-07	2014-08-13	IP Gesellschaft für Management mbH	Inhibitors of nedd8-activating enzyme
EP2815749A1 (en)	2013-06-20	2014-12-24	IP Gesellschaft für Management mbH	Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
CN103610658B (zh) *	2013-11-15	2017-04-12	广州帝奇医药技术有限公司	一种免疫调节剂缓释剂及其制备方法
EP3827836A1 (en)	2014-06-27	2021-06-02	Celgene Corporation	Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
US9499514B2 (en) *	2014-07-11	2016-11-22	Celgene Corporation	Antiproliferative compounds and methods of use thereof
US10034872B2 (en)	2014-08-22	2018-07-31	Celgene Corporation	Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
WO2016201337A1 (en) *	2015-06-12	2016-12-15	Immungene, Inc.	Engineered antibody-interferon fusion molecules for the treatment of glucose-regulated protein 94 (grp94) expressing cancers
US10001483B2 (en)	2015-06-26	2018-06-19	Celgene Corporation	Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
PT3385395T (pt)	2015-08-17	2020-05-06	Kura Oncology Inc	Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
AU2016378723B2 (en)	2015-12-22	2021-09-30	SHY Therapeutics LLC	Compounds for the treatment of cancer and inflammatory disease
WO2017117118A1 (en)	2015-12-28	2017-07-06	Celgene Corporation	Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
WO2018013693A1 (en)	2016-07-13	2018-01-18	Celgene Corporation	Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof
WO2018013689A1 (en)	2016-07-13	2018-01-18	Celgene Corporation	Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
US20180238886A1 (en) *	2017-01-31	2018-08-23	Celgene Corporation	Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds
US10093647B1 (en)	2017-05-26	2018-10-09	Celgene Corporation	Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
US10093649B1 (en)	2017-09-22	2018-10-09	Celgene Corporation	Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
US10093648B1 (en)	2017-09-22	2018-10-09	Celgene Corporation	Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
WO2019113269A1 (en)	2017-12-08	2019-06-13	Kura Oncology, Inc.	Methods of treating cancer patients with farnesyltransferase inhibitors
US11452722B2 (en) *	2018-01-11	2022-09-27	Natco Pharma Limited	Stable pharmaceutical compositions comprising lenalidomide
CA3211506A1 (en)	2018-02-07	2019-08-15	Lovelace Biomedical Research Institute	Inhalable dry powder cytidine analogue composition and method of use as a treatment for cancer
US20220142983A1 (en)	2019-03-01	2022-05-12	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
WO2020190604A1 (en)	2019-03-15	2020-09-24	Kura Oncology, Inc.	Methods of treating cancer patients with farnesyltransferase inhibitors
EP4069245A1 (en)	2019-12-02	2022-10-12	Celgene Corporation	Therapy for the treatment of cancer
AR129053A1 (es)	2022-04-14	2024-07-10	Bristol Myers Squibb Co	Nuevos compuestos gspt1 y métodos de uso de los nuevos compuestos

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3536809A (en) *	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en) *	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en) *	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en) *	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) *	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) *	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US5391485A (en) *	1985-08-06	1995-02-21	Immunex Corporation	DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) *	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) *	1985-08-23	1988-03-10	麒麟麦酒株式会社	多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US5073543A (en) *	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) *	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) *	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) *	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) *	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
AU1531492A (en)	1991-02-14	1992-09-15	Rockefeller University, The	Method for controlling abnormal concentration tnf alpha in human tissues
US5580578A (en) *	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en) *	1992-12-24	1994-11-01	The Whitaker Corporation	Wire retainer for current mode coupler
US5591767A (en) *	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
US5629327A (en) *	1993-03-01	1997-05-13	Childrens Hospital Medical Center Corp.	Methods and compositions for inhibition of angiogenesis
US20010056114A1 (en) *	2000-11-01	2001-12-27	D'amato Robert	Methods for the inhibition of angiogenesis with 3-amino thalidomide
US6114355A (en) *	1993-03-01	2000-09-05	D'amato; Robert	Methods and compositions for inhibition of angiogenesis
US8143283B1 (en) *	1993-03-01	2012-03-27	The Children's Medical Center Corporation	Methods for treating blood-born tumors with thalidomide
US6228879B1 (en) *	1997-10-16	2001-05-08	The Children's Medical Center	Methods and compositions for inhibition of angiogenesis
GB9515279D0 (en) *	1995-07-25	1995-09-20	Norsk Hydro As	Improved therapeutic agents
US5698579A (en) *	1993-07-02	1997-12-16	Celgene Corporation	Cyclic amides
US6077822A (en) *	1993-09-14	2000-06-20	Dumex-Alpharma A/S	Drug salts
IT1270594B (it) *	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
KR100405116B1 (ko) *	1995-02-28	2004-02-05	아벤티스 파마슈티칼스 인크.	피페리디노알칸올화합물에대한약제학적조성물
US5731325A (en) *	1995-06-06	1998-03-24	Andrulis Pharmaceuticals Corp.	Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
RU2118532C1 (ru) *	1996-04-10	1998-09-10	Олег Викторович Травкин	Противоинфекционное, противовоспалительное и противоопухолевое лекарственное средство
US5798368A (en) *	1996-08-22	1998-08-25	Celgene Corporation	Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
EP1285916B1 (en)	1996-07-24	2010-03-10	Celgene Corporation	Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNF alpha levels
HU228769B1 (en)	1996-07-24	2013-05-28	Celgene Corp	Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US6281230B1 (en) *	1996-07-24	2001-08-28	Celgene Corporation	Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) *	1996-07-24	1999-06-29	Celgene Corp	Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
EP0918746B1 (en) *	1996-08-12	2003-04-09	Celgene Corporation	Immunotherapeutic agents and their use in the reduction of cytokine levels
ES2253787T3 (es) *	1996-11-05	2006-06-01	The Children's Medical Center Corporation	Composiciones para inhibicion de la angiogenesis que comprenden talidomida y un nsaid.
KR20000057137A (ko) *	1996-11-19	2000-09-15	스티븐 엠. 오드레	아릴 및 헤테로아릴로 치환된 융합 피롤 항염증제
US5955476A (en) *	1997-11-18	1999-09-21	Celgene Corporation	Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US5874448A (en) *	1997-11-18	1999-02-23	Celgene Corporation	Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
SE9704545D0 (sv) *	1997-12-05	1997-12-05	Astra Pharma Prod	Novel compounds
US5919813C1 (en) *	1998-03-13	2002-01-29	Univ Johns Hopkins Med	Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
BR9908811A (pt) *	1998-03-16	2000-12-05	Celgene Corp	Composto, composição farmacêutica e seu uso no tratamento de mamìferos
US6673828B1 (en) *	1998-05-11	2004-01-06	Children's Medical Center Corporation	Analogs of 2-Phthalimidinoglutaric acid
US6020358A (en) *	1998-10-30	2000-02-01	Celgene Corporation	Substituted phenethylsulfones and method of reducing TNFα levels
US20030013739A1 (en) *	1998-12-23	2003-01-16	Pharmacia Corporation	Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
ES2250121T3 (es) *	1999-03-18	2006-04-16	Celgene Corporation	1-oxo- y 1,3-dioxoisoindolinas y su empleo en composiciones farmaceuticas para la reduccion de niveles de las citocinas inflamatorias.
US6228756B1 (en) *	1999-08-10	2001-05-08	United Microelectronics Corp.	Method of manufacturing inter-metal dielectric layer
US7182953B2 (en) *	1999-12-15	2007-02-27	Celgene Corporation	Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6326388B1 (en) *	1999-12-21	2001-12-04	Celgene Corporation	Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
CA2319872C (en) *	2000-02-02	2012-06-19	Chun-Ying Huang	Pharmaceutical composition for the treatment of hepatocellular carcinoma
CN1429121A (zh)	2000-03-17	2003-07-09	细胞治疗公司	聚谷氨酸－喜树碱结合物及其制备方法
KR20030003708A (ko) *	2000-03-31	2003-01-10	셀진 코포레이션	시클로옥시게나제-2 활성의 저해
KR100790589B1 (ko)	2000-05-15	2008-01-02	셀겐코포레이션	암 치료용 조성물 및 치료 방법
JP2004512262A (ja) *	2000-06-20	2004-04-22	アイデック　ファーマスーティカルズ　コーポレイション	非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ
WO2002015926A1 (en)	2000-08-24	2002-02-28	Kirin Beer Kabushiki Kaisha	c-mpl LIGAND-CONTAINING MEDICINAL COMPOSITIONS FOR INCREASING PLATELETS AND ERYTHROCYTES
US6458810B1 (en) *	2000-11-14	2002-10-01	George Muller	Pharmaceutically active isoindoline derivatives
CA2430669C (en)	2000-11-30	2011-06-14	The Children's Medical Center Corporation	Synthesis of 3-amino-thalidomide and its enantiomers
US20020128228A1 (en) *	2000-12-01	2002-09-12	Wen-Jen Hwu	Compositions and methods for the treatment of cancer
ES2522890T3 (es)	2000-12-06	2014-11-19	Anthrogenesis Corporation	Método para recolectar células troncales placentarias
US7091353B2 (en) *	2000-12-27	2006-08-15	Celgene Corporation	Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en)	2000-12-27	2003-03-06	Robarge Michael J.	Isoindole-imide compounds, compositions, and uses thereof
IL157350A0 (en)	2001-02-14	2004-02-19	Anthrogenesis Corp	Post-partum mammalian placenta, its use and placental stem cells therefrom
JP4361273B2 (ja) *	2001-02-27	2009-11-11	アメリカ合衆国	潜在的な血管形成阻害剤としてのサリドマイド類似体
US6734177B2 (en)	2001-04-17	2004-05-11	Novartis Ag	Certain salts of discodermolide acid, pharmaceutical compositions containing them and their use in treating tumors
US7361341B2 (en) *	2001-05-25	2008-04-22	Human Genome Sciences, Inc.	Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
AU2002323063B2 (en)	2001-08-06	2007-11-08	Entremed, Inc.	Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
WO2003039545A2 (en) *	2001-11-07	2003-05-15	Millennium Pharmaceuticals, Inc.	Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
CA2478338A1 (en) *	2002-03-08	2003-09-18	Signal Pharmaceuticals, Inc.	Combination therapy for treating, preventing or managing proliferative disorders and cancers
US7498171B2 (en) *	2002-04-12	2009-03-03	Anthrogenesis Corporation	Modulation of stem and progenitor cell differentiation, assays, and uses thereof
ZA200408369B (en)	2002-04-12	2006-11-29	Celgene Corp	Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
US7968569B2 (en) *	2002-05-17	2011-06-28	Celgene Corporation	Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP2272513A1 (en) *	2002-05-17	2011-01-12	Celgene Corporation	Pharmaceutical compositions for treating cancer
US7323479B2 (en) *	2002-05-17	2008-01-29	Celgene Corporation	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7393862B2 (en) *	2002-05-17	2008-07-01	Celgene Corporation	Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
EP1542531A4 (en)	2002-05-24	2011-01-05	Sicor Inc	Aqueous fludarabine phosphorus composition
US8404716B2 (en) *	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7189740B2 (en) *	2002-10-15	2007-03-13	Celgene Corporation	Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20040091455A1 (en) *	2002-10-31	2004-05-13	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) *	2002-11-06	2009-07-21	Celgene Corporation	Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US7189746B2 (en) *	2002-11-08	2007-03-13	Gliamed, Inc.	Methods for promoting wound healing
US8586298B2 (en) *	2002-11-19	2013-11-19	Clluone Diagnostics A/S	Methods and kits for diagnosing and treating b-cell chronic lymphocytic leukemia
CA2516627A1 (en) *	2003-02-28	2004-09-16	Bayer Pharmaceuticals Corporation	Substituted pyridine derivatives useful in the treatment of cancer and other disorders
CL2004001004A1 (es) *	2003-05-19	2005-03-18	Upjohn Co	Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple.
US6733566B1 (en) *	2003-06-09	2004-05-11	Alcoa Inc.	Petroleum coke melt cover for aluminum and magnesium alloys
WO2005011598A2 (en) *	2003-07-31	2005-02-10	University Of South Florida	Leukemia treatment method and composition

2005
- 2005-10-04 US US11/244,117 patent/US7393862B2/en not_active Expired - Lifetime
2006
- 2006-03-10 UA UAA200805327A patent/UA94062C2/ru unknown
- 2006-10-03 CA CA002570755A patent/CA2570755A1/en not_active Abandoned
- 2006-10-03 CN CN2013100490881A patent/CN103142594A/zh active Pending
- 2006-10-03 KR KR1020087010897A patent/KR20080058469A/ko not_active Ceased
- 2006-10-03 JP JP2008534665A patent/JP5916977B2/ja active Active
- 2006-10-03 KR KR1020167023898A patent/KR20160105940A/ko not_active Ceased
- 2006-10-03 NZ NZ567049A patent/NZ567049A/en unknown
- 2006-10-03 CA CA2972299A patent/CA2972299A1/en not_active Abandoned
- 2006-10-03 BR BRPI0616670-9A patent/BRPI0616670A2/pt not_active Application Discontinuation
- 2006-10-03 RU RU2008117432/15A patent/RU2406501C2/ru not_active IP Right Cessation
- 2006-10-03 EP EP06816250A patent/EP1931343A2/en not_active Ceased
- 2006-10-03 KR KR1020147014746A patent/KR20140082857A/ko not_active Ceased
- 2006-10-03 AU AU2006299431A patent/AU2006299431B2/en active Active
- 2006-10-03 CN CNA2006800441296A patent/CN101316588A/zh active Pending
- 2006-10-03 PE PE2006001200A patent/PE20070761A1/es not_active Application Discontinuation
- 2006-10-03 AR ARP060104355A patent/AR057868A1/es unknown
- 2006-10-03 WO PCT/US2006/038844 patent/WO2007041637A2/en not_active Ceased
- 2006-10-03 EP EP12171482A patent/EP2526946A1/en not_active Withdrawn
- 2006-10-04 TW TW095136901A patent/TWI415610B/zh active
2008
- 2008-02-19 US US12/070,451 patent/US8440194B2/en not_active Expired - Fee Related
- 2008-03-25 IL IL190437A patent/IL190437A/en active IP Right Grant
- 2008-04-30 NO NO20082068A patent/NO20082068L/no not_active Application Discontinuation
- 2008-10-03 ZA ZA200803700A patent/ZA200803700B/xx unknown
2010
- 2010-09-07 RU RU2010137395/15A patent/RU2010137395A/ru unknown
2011
- 2011-12-02 US US13/310,543 patent/US8632787B2/en not_active Expired - Lifetime
2013
- 2013-01-16 JP JP2013005399A patent/JP2013091659A/ja active Pending
- 2013-05-08 US US13/889,473 patent/US8623384B2/en not_active Expired - Fee Related
- 2013-12-31 US US14/145,171 patent/US9056103B2/en not_active Expired - Lifetime
2014
- 2014-09-17 JP JP2014188693A patent/JP2015044811A/ja active Pending
2015
- 2015-06-03 US US14/729,934 patent/US9498472B2/en not_active Expired - Fee Related
2016
- 2016-10-17 US US15/295,910 patent/US20170095464A1/en not_active Abandoned
2017
- 2017-07-13 JP JP2017136968A patent/JP2017222686A/ja active Pending

Also Published As

Publication number	Publication date
US20130251709A1 (en)	2013-09-26
ZA200803700B (en)	2010-02-24
IL190437A (en)	2017-03-30
RU2406501C2 (ru)	2010-12-20
CA2570755A1 (en)	2007-04-04
US20060030594A1 (en)	2006-02-09
AR057868A1 (es)	2007-12-26
JP2009510171A (ja)	2009-03-12
US9498472B2 (en)	2016-11-22
US20170095464A1 (en)	2017-04-06
US20080145368A1 (en)	2008-06-19
JP2015044811A (ja)	2015-03-12
US20140112920A1 (en)	2014-04-24
US20150265591A1 (en)	2015-09-24
TW200730175A (en)	2007-08-16
EP2526946A1 (en)	2012-11-28
WO2007041637A2 (en)	2007-04-12
US20120135042A1 (en)	2012-05-31
BRPI0616670A2 (pt)	2011-06-28
CA2972299A1 (en)	2007-04-04
RU2010137395A (ru)	2012-03-20
KR20080058469A (ko)	2008-06-25
US8440194B2 (en)	2013-05-14
US8623384B2 (en)	2014-01-07
AU2006299431A1 (en)	2007-04-12
IL190437A0 (en)	2008-11-03
TWI415610B (zh)	2013-11-21
CN101316588A (zh)	2008-12-03
KR20140082857A (ko)	2014-07-02
RU2008117432A (ru)	2009-11-10
US9056103B2 (en)	2015-06-16
CN103142594A (zh)	2013-06-12
JP2017222686A (ja)	2017-12-21
WO2007041637A3 (en)	2007-08-09
PE20070761A1 (es)	2007-09-10
EP1931343A2 (en)	2008-06-18
US8632787B2 (en)	2014-01-21
NZ567049A (en)	2011-07-29
AU2006299431B2 (en)	2011-11-10
KR20160105940A (ko)	2016-09-07
US7393862B2 (en)	2008-07-01
JP5916977B2 (ja)	2016-05-11
JP2013091659A (ja)	2013-05-16
NO20082068L (no)	2008-07-02

Publication	Publication Date	Title
UA94062C2 (en)	2011-04-11	Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of leukemia
IL178747A0 (en)	2007-02-11	Methods for treatment of certain cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
CY1110989T1 (el)	2015-06-11	Χρηση 3-(4-αμινο-1-οξο-1,3-διυδρο-ισοϊνδολ-2-υλο)-πιπεριδινο-2,6-διονης για την αντιμετωπιση λεμφωματων κυτταρων του μανδυα
MX2009001130A (es)	2009-05-13	Metodos para usar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(met ilamino)-1-pirrolidinil]-4-oxo-1(2-tiazolil)-1,8-naftiridina-3-ca rboxilico para el tratamiento de ciertos padecimientos hematologicos.
MXPA05012155A (es)	2006-02-22	Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
WO2009075841A3 (en)	2009-08-06	Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
TW200500355A (en)	2005-01-01	Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
NO20090469L (no)	2009-03-27	Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
MX361467B (es)	2018-12-06	Compuestos de isoindolina para uso en el tratamiento de cancer.
MX2009007337A (es)	2009-07-15	Indazoles sustituidos con 5-piridinona.
EP2479290A3 (en)	2012-10-10	Methods for the administration of iloperidone
JO2645B1 (en)	2012-06-17	Vehicles
IL188942A0 (en)	2008-04-13	Benzimidazole derivatives and pharmaceutical compositions containing the same
MX2008015775A (es)	2009-04-17	Compuestos y composiciones para tratamiento de cancer.
WO2005046593A3 (en)	2006-03-02	Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
MX2010008220A (es)	2010-08-23	Metodos que usan compuestos inmunomoduladores para modular nivel de cd59.
MY164998A (en)	2018-02-28	Isoquinolinone derivatives as nk3 antagonists
MXPA05013478A (es)	2006-03-09	Combinaciones terapeuticas.
GB0611907D0 (en)	2006-07-26	Compounds
MX2010005009A (es)	2010-05-27	Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.
WO2009073146A3 (en)	2009-08-06	Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders
AU2013219242C1 (en)	2016-09-22	Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
MD17Y (en)	2009-04-30	Method for treating stable anxious depressive states
UA105483C2 (ru)	2014-05-26	Производные изохинолинона, композиция на их основе и применение в качестве ингибиторов pi3k